HIPGNOSIS SONGS FUND LIMITED financials
HIPGNOSIS SONGS FUND LIMITED
213800XJIPNDVKXMOC11 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | $177.3M | $200.4M |
| Operating expenses | $233.9M | $185.0M |
| Profit before tax | -$86.6M | -$16.7M |
| Income tax expense | $3.0M | $2.7M |
| Profit for the year | -$89.6M | -$19.4M |
| Total comprehensive income | -$89.6M | -$21.3M |
| Per share | ||
| Basic EPS | $-0.07 | $-0.02 |
| Diluted EPS | $-0.07 | $-0.02 |
| Cash flow statement | ||
| Net cash from operating activities | $102.1M | $84.9M |
| Net cash from investing activities | -$6.6M | -$309.1M |
| Purchase of intangibles | $0 | $300.5M |
| Net cash from financing activities | -$88.4M | $141.5M |
| Dividends paid | $56.3M | $84.3M |
| Proceeds from borrowings | $1.8M | $72.7M |
| Repayments of borrowings | $7.0M | $50.0M |
| Net change in cash | $7.1M | -$82.8M |
| Balance sheet | ||
| Total assets | $2.12B | $2.21B |
| Non-current assets | $1.94B | $2.04B |
| Intangible assets & goodwill | $272.0K | $272.0K |
| Current assets | $182.9M | $174.5M |
| Trade & other receivables | $140.0M | $144.4M |
| Cash & equivalents | $38.0M | $30.1M |
| Total equity | $1.43B | $1.58B |
| — attributable to owners | $1.43B | $1.58B |
| Non-current liabilities | $627.5M | $594.9M |
| Long-term borrowings | $594.4M | $594.0M |
| Current liabilities | $56.5M | $35.4M |
| Trade & other payables | $53.1M | $35.4M |
| Derived metrics | ||
| Net margin | -50.6% | -9.7% |
| Return on equity | -6.2% | -1.2% |
| Cash conversion ratio | -1.14× | -4.37× |
| Other reported items | ||
| Adjustments For Amortisation Expense | $113.2M | $107.4M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -$14.0M | -$37.3M |
| Adjustments For Depreciation Expense | $653.0K | $712.0K |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | $2.6M | $0 |
| Adjustments For Impairment Loss Recognised In Profit Or Loss Goodwill | $3.9M | $1.5M |
| Adjustments For Increase Decrease In Trade and Other Payables | $3.9M | -$1.5M |
| Adjustments For Provisions | $1.0M | $0 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | $3.2M | $14.9M |
| Auditors Remuneration | $753.0K | $600.0K |
| Brokerage Fee Expense | $554.0K | $274.0K |
| Cash Advances and Loans Made To Other Parties Classified As Investing Activities | $4.0M | $8.5M |
| Copyrights Patents and Other Industrial Property Rights Service and Operating Rights | $1.92B | $2.04B |
| Current Derivative Financial Assets | $4.9M | $0 |
| Current Derivative Financial Liabilities | $3.4M | $0 |
| Depreciation Expense | $653.0K | $712.0K |
| Directors Remuneration Expense | $643.0K | $696.0K |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | $0.01 | — |
| Dividends Recognised As Distributions To Owners Per Share | $0.04 | $0.05 |
| Gains Losses On Change In Fair Value of Derivatives | $2.6M | $0 |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -$3.2M | -$14.9M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $3.9M | $1.5M |
| Income Taxes Paid Refund Classified As Operating Activities | $5.4M | $6.0M |
| Increase Decrease In Cash and Cash Equivalents | $795.0K | $228.0K |
| Interest Expense On Borrowings | $33.7M | $20.4M |
| Issue of Equity | — | $229.5M |
| Issued Capital | $1.69B | $1.69B |
| Liabilities | $684.0M | $630.3M |
| Miscellaneous Other Operating Expense | $10.4M | $10.1M |
| Net Assets Liabilities | $1.43B | $1.58B |
| Noncurrent Receivables | $13.2M | $640.0K |
| Number of Shares Outstanding | 1209.2M | 1211.2M |
| Other Comprehensive Income | -$6.0K | -$1.8M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -$6.0K | -$1.8M |
| Other Finance Cost | $0 | $212.0K |
| Other Noncurrent Assets | $917.0K | $568.0K |
| Payments For Share Issue Costs | $0 | $4.4M |
| Payments To Acquire Or Redeem Entitys Shares | $2.0M | $0 |
| Proceeds From Issuing Shares | $0 | $229.5M |
| Professional Fees Expense | $3.8M | $6.0M |
| Purchase of Other Longterm Assets Classified As Investing Activities | $51.0K | $173.0K |
| Purchase of Treasury Shares | $2.0M | — |
| Reserve of Exchange Differences On Translation | -$2.2M | -$2.2M |
| Retained Earnings | -$253.5M | -$107.6M |
| Revenue From Interest | $237.0K | $5.0K |
| Royalty Expense | $30.3M | $32.0M |
| Share Issue Related Cost | — | $4.4M |
| Share of Profit Loss of Joint Ventures Accounted For Using Equity Method | -$264.0K | -$836.0K |
| Treasury Shares | $2.0M | $0 |
Every line item above is a fact tagged in HIPGNOSIS SONGS FUND LIMITED's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.